Health Topics — Skin & Topical
CBG and Skin Inflammation: Preclinical Research
CBG reduced abnormal skin cell proliferation in keratinocyte cell cultures — what the Wilkinson study found, the mechanism it identified, and what cell culture evidence can and cannot establish about living skin.
Procedural Note
Psoriasis is a chronic immune-mediated condition managed under dermatologist care. Established topical, systemic, and biological treatments exist. This article discusses preclinical cell culture research only. Nothing here constitutes guidance on managing psoriasis or any other skin condition. People with psoriasis should work with their dermatologist on treatment decisions.
Psoriasis involves keratinocytes — the skin's primary structural cells — proliferating far faster than normal, driven by dysregulated immune signaling in the skin. That specific cellular mechanism is what makes CBG a research subject in this context: the question is whether CBG's documented effects on cell proliferation and inflammatory signaling are relevant to what goes wrong in psoriatic skin.
What Psoriasis Is and Why Keratinocytes Are Central
Psoriasis is an immune-mediated inflammatory condition in which T cells in the skin — activated by poorly understood triggers — release cytokines that drive keratinocytes to proliferate abnormally. Keratinocytes — the cells that form the outermost layer of the skin — normally take approximately 28 days to mature and reach the skin surface, where they are shed. In psoriatic skin, this process is compressed to three to five days. The result is that immature keratinocytes accumulate faster than they can shed, producing the thickened, scaly plaques characteristic of the condition.
The immune driver and the keratinocyte response are inseparable in psoriasis. The condition is not simply a skin cell proliferation disorder, and it is not simply an immune disorder — it is a dysregulated dialogue between skin-resident immune cells and keratinocytes, sustained by cytokine loops that keep both sides of the response active. Effective treatments either interrupt the immune signaling (biological agents targeting TNF-α, IL-17, IL-23) or directly suppress keratinocyte proliferation (topical corticosteroids, vitamin D analogues, retinoids). Understanding which mechanisms are relevant to CBG's research profile requires knowing which side of that dialogue is being examined.
The ECS in Skin — Receptor Distribution and Local Signaling
Keratinocytes express both CB1 and CB2 receptors, as well as TRPV1 channels and PPAR-γ nuclear receptors — four distinct molecular targets with documented cannabinoid interactions. They also produce endocannabinoids locally, including anandamide and 2-AG, suggesting the ECS operates as an autocrine and paracrine signaling system within skin tissue — cells communicating with themselves and with adjacent cells through locally produced cannabinoids rather than relying entirely on systemic endocannabinoid tone.
The Wilkinson Study — Design and Findings
Study Design: Cell culture study using human keratinocyte cell lines. Keratinocytes were grown in laboratory conditions and exposed to cannabinoids including CBG, CBD, THC, and CBC at various concentrations. The primary outcome measured was the effect on keratinocyte proliferation rate — how quickly the cells divided — compared to untreated controls.
CBG Findings: CBG inhibited keratinocyte proliferation in a concentration-dependent manner — higher concentrations produced greater inhibition of cell division. The effect was statistically significant relative to controls. CBG's antiproliferative potency in this model was comparable to CBD and stronger than CBC across the concentrations tested.
Mechanism Explored: The study examined receptor involvement by testing whether known CB1 and CB2 antagonists could block the antiproliferative effects. Results suggested the effects were not fully explained by CB1 or CB2 activation alone, pointing toward additional mechanisms — consistent with CBG's known activity at PPAR-γ and its capacity to interact with multiple molecular targets. The relative contribution of each pathway was not definitively resolved.
What the Study Establishes: CBG reduces the rate of keratinocyte cell division in laboratory culture conditions. This is a clean, direct finding with a plausible mechanistic basis and relevance to the specific cellular abnormality in psoriasis. It is also a cell culture finding — isolated keratinocytes in a dish, not inflamed skin tissue, not a living organism, not a person with psoriasis.
What Cell Culture Cannot Establish
The gap between a keratinocyte cell culture finding and a treatment for psoriasis is substantial and worth describing specifically rather than gesturing at vaguely.
Psoriatic keratinocyte hyperproliferation is driven by immune signaling — cytokines released by activated T cells in the skin stimulate keratinocytes to divide faster than normal. Demonstrating that CBG slows keratinocyte proliferation in the absence of that immune signaling pressure does not establish that CBG would slow it in the presence of the full psoriatic cytokine environment. The cell culture model and the disease model are not the same experiment.
Bioavailability to skin tissue is a separate challenge. CBG taken orally or sublingually must reach dermal and epidermal tissue at concentrations sufficient to produce the effects observed in cell culture. Topical application raises different questions about skin penetration — the stratum corneum, the outermost skin layer, is designed to resist penetration by most molecules, and the concentrations that reach living keratinocytes through topical application of a hemp extract are unknown. Neither route of administration has been studied for CBG specifically in skin tissue in humans.
CBD and Skin — A Broader Evidence Base
CBD's skin inflammation evidence base is somewhat broader than CBG's. In addition to keratinocyte antiproliferative effects comparable to CBG in the Wilkinson study, CBD has documented TRPV1 activity relevant to itch signaling, and a small number of observational studies and open-label trials in humans with psoriasis and eczema have been published — though these are methodologically limited and do not constitute clinical trial evidence. The TRPV1 mechanism is particularly relevant to the sensory symptom burden of inflammatory skin conditions.
CBG and CBD are not interchangeable in a skin context. Their receptor profiles overlap in some areas (CB2, PPAR-γ) and diverge in others (TRPV1 — primarily CBD; partial vs. full agonism at CB2). Full-spectrum preparations contain both, which complicates attribution of any observed effect to a single compound.
The Honest Evidence Summary
CBG inhibits keratinocyte proliferation in cell culture — a finding that is mechanistically relevant to psoriasis, clearly documented, and limited to an in vitro model. The mechanisms involved (CB1/CB2, PPAR-γ) are consistent with CBG's broader pharmacological profile. The Wilkinson study is the primary evidence in this domain.
No animal model studies of CBG in psoriasis or other inflammatory skin conditions have been published as of 2026. No human trials exist. The distance from a cell culture antiproliferative finding to a treatment for a complex immune-mediated skin condition is significant. Psoriasis is managed effectively by dermatologists using established treatments — this research does not constitute an alternative to that care.
References
- Wilkinson, J.D., & Williamson, E.M. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science, 45(2), 87–92.
- Bíró, T., Tóth, B.I., Haskó, G., et al. (2009). The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences, 30(8), 411–420.
- Oláh, A., Tóth, B.I., Borbíró, I., et al. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Journal of Clinical Investigation, 124(9), 3713–3724.
- Tóth, K.F., Ádám, D., Bíró, T., & Oláh, A. (2019). Cannabinoid signaling in the skin: Therapeutic potential of the "C(ut)annabinoid" system. Molecules, 24(5), 918.
- Pucci, M., Rapino, C., Di Francesco, A., et al. (2013). Epigenetic control of skin differentiation genes by phytocannabinoids. British Journal of Pharmacology, 170(3), 581–591.
- Scheau, C., Badarau, I.A., Mihai, L.G., et al. (2020). Cannabinoids in the pathophysiology of skin inflammation. Molecules, 25(3), 652.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.